Litcius/Paper detail

Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy

Suthinee Ithimakin, Pathra Theeratrakul, Apirom Laocharoenkiat, Akarin Nimmannit, Charuwan Akewanlop, Nopadol Soparattanapaisarn, Sirisopa Techawattanawanna, Krittiya Korphaisarn, Pongwut Danchaivijitr

2020Supportive Care in Cancer27 citationsDOI

Topics & Concepts

MedicineAprepitantOndansetronNauseaVomitingChemotherapyAntiemeticAnesthesiaOlanzapinePlaceboDexamethasonePain medicineDoseRandomized controlled trialInternal medicineAnesthesiologyPsychiatrySchizophrenia (object-oriented programming)PathologyAlternative medicineNausea and vomiting managementChemotherapy-induced organ toxicity mitigationChemotherapy-related skin toxicity
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy | Litcius